AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
Portfolio Pulse from Benzinga Newsdesk
AbCellera and Biogen Inc. have announced a strategic collaboration to discover antibodies for a novel target that could enable the delivery of biotherapeutics to the brain, focusing on neurological conditions. AbCellera will receive an upfront payment and may also receive additional milestone payments and royalties on future net sales of products arising from this collaboration.
March 11, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbCellera enters a strategic collaboration with Biogen to discover therapeutic antibodies, receiving an upfront payment with potential for more based on milestones and future sales.
The collaboration with Biogen not only provides immediate financial benefits to AbCellera through an upfront payment but also opens up potential for significant future revenues through milestone payments and royalties. This partnership could enhance AbCellera's financial stability and fuel further research and development efforts.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Biogen collaborates with AbCellera to discover antibodies for neurological conditions, aiming to cross the blood-brain barrier, a significant challenge in neuroscience.
For Biogen, this collaboration represents a strategic investment in overcoming one of neuroscience's biggest hurdles: the delivery of biologics across the blood-brain barrier. Success in this area could lead to groundbreaking treatments for neurological conditions, potentially boosting Biogen's product portfolio and market position.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90